Sino Biopharmaceutical Ltd
01177: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$6.31 | Tvqf | Mmtsjhf |
Sino Biopharmaceutical's First-Quarter Earnings in Line, Back on Track for Growth
Narrow-moat Sino Biopharmaceuticals, or SBP, reported first-quarter earnings that were in line with our expectations. We maintain our fair value estimate of HKD 6.50. With the stock trading at a 33% premium to our fair value, we view the stock as overpriced and believe other stocks offer better value, especially smaller and nimbler biotech companies like Innovent and Junshi.